Hub : Traits :

Heart attack/myocardial infarction (self-reported)

40 significantly associated models · 13 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 109098737 110517617 2 1 4.7e-09 3.9e-09 2.7e-01 96 PSRC1
2 1 222096959 223567803 3 1 2.4e-12 3.5e-12 1.0e+00 100 RP11-378J18.8
3 3 135861666 137253713 1 1 2.8e-07 1.1e-07 8.0e-02 89 RP11-731C17.2
4 6 12020241 13990267 2 1 1.1e-16 1.0e-16 3.8e-02 94 RP1-257A7.5
5 6 159820779 161571560 2 2 5.3e-09 4.8e-12 1.3e-08 32 RP11-288H12.3 SLC22A3
6 9 21303958 22819407 2 2 7.3e-16 6.8e-31 8.3e-16 52 CDKN2B CDKN2B-AS1
7 15 90730363 92135418 1 1 1.6e-07 2.8e-06 8.7e-01 100 FES

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Irritable Bowel Disease (IBD) 0.84 1 0 0.0 0.00 1.0e+00 FES
Major Depression (MDD) 2.64 1 0 0.0 0.00 1.0e+00 FES
Breast Cancer 3.15 3 0 0.0 0.00 1.0e+00 CDKN2B CDKN2B-AS1 FES
Coronary Artery Disease (CAD) 27.78 6 4 12.1 -0.99 3.0e-04 CDKN2B CDKN2B-AS1 FES PSRC1 RP1-257A7.5 SLC22A3
HDL Cholesterol 3.46 2 0 0.0 0.00 1.0e+00 PSRC1 RP11-731C17.2
LDL Cholesterol 57.81 2 1 3.0 0.00 1.0e+00 PSRC1 RP11-288H12.3
Schizophrenia 3.49 2 1 3.0 0.00 1.0e+00 FES RP11-731C17.2
Triglycerides 3.25 2 0 0.0 0.00 1.0e+00 RP11-288H12.3 RP11-731C17.2
Type 2 Diabetes (T2D) 3.12 1 0 0.0 0.00 1.0e+00 CDKN2B
Blood Eosinophil Count 0.55 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Blood Platelet Count 1.15 3 1 3.0 0.00 1.0e+00 CDKN2B RP11-731C17.2 SLC22A3
Blood Red Count 0.63 2 0 0.0 0.00 1.0e+00 FES RP1-257A7.5
Blood White Count 2.15 4 2 6.1 -0.53 4.7e-01 CDKN2B FES RP11-731C17.2 RP1-257A7.5
Heel T-Score 0.62 2 1 3.0 0.00 1.0e+00 PSRC1 RP11-731C17.2
BMI 2.32 3 1 3.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Height 1.35 5 5 15.2 0.98 3.3e-03 FES PSRC1 RP11-288H12.3 RP11-731C17.2 SLC22A3
Waist Hip Ratio (WHR) 2.82 4 1 3.0 -0.91 8.7e-02 RP11-288H12.3 RP11-378J18.8 RP11-731C17.2 SLC22A3
Systolic Blood Pressure 8.26 3 2 6.1 0.00 1.0e+00 FES RP1-257A7.5 SLC22A3
Smoking Status 2.14 2 0 0.0 0.00 1.0e+00 FES PSRC1
Allergy or Eczema 1.58 1 0 0.0 0.00 1.0e+00 FES
Cardiovascular Disease 11.29 5 3 9.1 -0.98 4.0e-03 FES PSRC1 RP11-288H12.3 RP11-731C17.2 SLC22A3
Respiratory disease 1.96 1 0 0.0 0.00 1.0e+00 FES
Type 2 Diabetes (T2D) 2.55 2 0 0.0 0.00 1.0e+00 RP11-731C17.2 SLC22A3
Lung FEV1/FVC ratio 1.44 2 1 3.0 0.00 1.0e+00 PSRC1 RP11-378J18.8
Lung FVC 0.73 1 0 0.0 0.00 1.0e+00 RP11-378J18.8
Neuroticism 1.38 2 0 0.0 0.00 1.0e+00 FES RP1-257A7.5
Hair Pigment 0.56 3 3 9.1 0.00 1.0e+00 CDKN2B CDKN2B-AS1 FES
Hand grip strength (left) 2.26 2 0 0.0 0.00 1.0e+00 FES RP1-257A7.5
Number of treatments/medications taken 4.30 3 1 3.0 0.00 1.0e+00 FES PSRC1 RP11-731C17.2
Sensitivity / hurt feelings 1.72 1 0 0.0 0.00 1.0e+00 FES
Hearing difficulty/problems: Yes 1.87 1 0 0.0 0.00 1.0e+00 RP11-378J18.8
Relative age of first facial hair 2.10 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Other serious medical condition/disability diagnosed by doctor 1.83 1 0 0.0 0.00 1.0e+00 PSRC1
Systolic blood pressure, automated reading 6.31 2 2 6.1 0.00 1.0e+00 FES RP1-257A7.5
Angina 28.90 8 5 15.2 0.97 1.0e-04 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP1-257A7.5 SLC22A3
Medication: Metformin 2.39 1 0 0.0 0.00 1.0e+00 CDKN2B
Impedance of leg (right) 2.00 4 1 3.0 -0.42 5.8e-01 FES PSRC1 RP11-378J18.8 RP11-731C17.2
Leg fat-free mass (left) 1.45 2 0 0.0 0.00 1.0e+00 FES SLC22A3
Trunk fat percentage 1.69 2 0 0.0 0.00 1.0e+00 RP1-257A7.5 SLC22A3
Hand grip strength (right) 1.86 2 0 0.0 0.00 1.0e+00 PSRC1 RP1-257A7.5
Relative age voice broke 1.96 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
High blood pressure 7.37 3 1 3.0 0.00 1.0e+00 FES RP11-731C17.2 RP1-257A7.5
Hayfever, allergic rhinitis or eczema 1.59 1 0 0.0 0.00 1.0e+00 FES
Multivitamins +/- minerals 2.00 1 0 0.0 0.00 1.0e+00 RP11-288H12.3
Medication: Atenolol 6.94 2 1 3.0 0.00 1.0e+00 CDKN2B FES
Sitting height 0.76 1 0 0.0 0.00 1.0e+00 SLC22A3
High blood pressure (mother) 7.61 2 1 3.0 0.00 1.0e+00 FES RP1-257A7.5
Body mass index (BMI) 1.79 2 1 3.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5
Impedance of leg (left) 1.91 3 1 3.0 0.00 1.0e+00 FES RP11-378J18.8 RP11-731C17.2
Leg predicted mass (left) 1.46 2 0 0.0 0.00 1.0e+00 FES SLC22A3
Trunk fat mass 1.74 2 0 0.0 0.00 1.0e+00 RP1-257A7.5 SLC22A3
Waist circumference 1.96 2 1 3.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5
Number of incorrect matches in round 1.80 1 0 0.0 0.00 1.0e+00 FES
Past tobacco smoking 2.70 1 0 0.0 0.00 1.0e+00 CDKN2B-AS1
Alcohol usually taken with meals 1.81 1 0 0.0 0.00 1.0e+00 FES
Nervous feelings 1.61 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Heart attack 33.43 9 8 24.2 1.00 1.6e-13 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP11-731C17.2 RP1-257A7.5 SLC22A3
Allergy 1.63 1 0 0.0 0.00 1.0e+00 FES
Medication: Ramipril 5.58 2 0 0.0 0.00 1.0e+00 FES SLC22A3
Medication: Simvastatin 18.29 6 2 6.1 0.95 3.6e-03 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-731C17.2 SLC22A3
Illnesses of siblings 3.33 1 0 0.0 0.00 1.0e+00 FES
Weight 1.53 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Impedance of arm (right) 2.24 3 1 3.0 0.00 1.0e+00 CDKN2B PSRC1 RP11-731C17.2
Arm fat percentage (right) 1.84 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Trunk fat-free mass 1.28 2 0 0.0 0.00 1.0e+00 PSRC1 SLC22A3
Hip circumference 2.01 2 1 3.0 0.00 1.0e+00 RP11-731C17.2 SLC22A3
Father's age at death 7.97 4 1 3.0 -1.00 3.5e-03 CDKN2B CDKN2B-AS1 FES PSRC1
Falls in the last year 2.35 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Number of live births 1.07 1 0 0.0 0.00 1.0e+00 FES
Noisy workplace 2.30 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Asthma 1.41 1 0 0.0 0.00 1.0e+00 FES
Medication: Ibuprofen (e.g. Nurofen) 5.77 3 1 3.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Medication: Cholesterol lowering 27.43 8 3 9.1 0.89 2.7e-03 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP11-731C17.2 SLC22A3
Illnesses of mother 6.02 2 1 3.0 0.00 1.0e+00 CDKN2B FES
Pulse wave Arterial Stiffness index 4.75 2 0 0.0 0.00 1.0e+00 FES RP1-257A7.5
Impedance of arm (left) 1.65 2 1 3.0 0.00 1.0e+00 PSRC1 RP11-731C17.2
Arm fat mass (right) 1.77 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Trunk predicted mass 1.27 2 0 0.0 0.00 1.0e+00 PSRC1 SLC22A3
Standing height 1.35 4 2 6.1 -0.98 1.7e-02 PSRC1 RP11-288H12.3 RP11-731C17.2 SLC22A3
Breastfed as a baby 1.75 1 0 0.0 0.00 1.0e+00 FES
Hair/balding pattern: Pattern 4 1.39 1 0 0.0 0.00 1.0e+00 FES
Birth weight of first child 4.28 1 1 3.0 0.00 1.0e+00 FES
Medication: Paracetamol 3.00 1 1 3.0 0.00 1.0e+00 RP1-257A7.5
Headache pain in last month 5.47 2 1 3.0 0.00 1.0e+00 FES RP1-257A7.5
Medication for cholesterol, blood pressure or diabetes 12.53 4 2 6.1 -0.86 1.4e-01 FES PSRC1 RP11-378J18.8 RP11-731C17.2
Glaucoma (self-reported) 7.23 2 1 3.0 0.00 1.0e+00 CDKN2B CDKN2B-AS1
Medication: Amlodipine 2.74 1 1 3.0 0.00 1.0e+00 FES
Birth weight 3.04 1 1 3.0 0.00 1.0e+00 FES
High blood pressure (siblings) 3.30 1 1 3.0 0.00 1.0e+00 FES
Body fat percentage 1.83 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Leg fat percentage (right) 2.36 2 1 3.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5
Arm fat-free mass (right) 1.28 3 0 0.0 0.00 1.0e+00 PSRC1 RP11-731C17.2 SLC22A3
Wheeze or whistling in the chest in last year 1.29 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Pulse wave peak to peak time 4.80 2 0 0.0 0.00 1.0e+00 FES RP1-257A7.5
Qualifications: College or University degree 1.04 1 0 0.0 0.00 1.0e+00 RP1-257A7.5
Medication for pain relief, constipation, heartburn 4.05 2 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5
Neck or shoulder pain in last month 2.56 1 0 0.0 0.00 1.0e+00 RP11-731C17.2
Medication: Blood pressure 6.23 1 1 3.0 0.00 1.0e+00 FES
Angina (self-reported) 29.91 8 5 15.2 0.97 7.9e-05 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP1-257A7.5 SLC22A3
Migraine (self-reported) 5.74 1 1 3.0 0.00 1.0e+00 RP1-257A7.5
Medication: Ibuprofen 5.66 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Mean time to correctly identify matches 2.04 1 0 0.0 0.00 1.0e+00 FES
Heart disease (mother) 14.56 7 2 6.1 0.98 1.2e-04 CDKN2B CDKN2B-AS1 FES RP11-288H12.3 RP11-378J18.8 RP1-257A7.5 SLC22A3
Whole body fat mass 1.85 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Leg fat mass (right) 1.87 3 1 3.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Arm predicted mass (right) 1.36 3 0 0.0 0.00 1.0e+00 PSRC1 RP11-731C17.2 SLC22A3
Pulse rate, automated reading 1.59 2 0 0.0 0.00 1.0e+00 RP11-378J18.8 RP1-257A7.5
Alcohol intake frequency. 2.04 1 0 0.0 0.00 1.0e+00 RP1-257A7.5
Comparative height size at age 10 1.29 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Chest pain or discomfort 3.34 1 0 0.0 0.00 1.0e+00 CDKN2B
Medication: Aspirin 17.44 7 5 15.2 0.99 6.5e-06 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-731C17.2 SLC22A3
Knee pain experienced in last month 1.31 1 0 0.0 0.00 1.0e+00 RP1-257A7.5
Hypertension (Self-reported) 7.57 4 1 3.0 0.42 5.8e-01 FES RP11-731C17.2 RP1-257A7.5 SLC22A3
Illnesses of father: Heart disease 30.56 9 6 18.2 0.97 2.4e-05 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP11-731C17.2 RP1-257A7.5 SLC22A3
Smoking status: Previous 2.56 1 0 0.0 0.00 1.0e+00 CDKN2B-AS1
Whole body fat-free mass 1.33 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Leg fat-free mass (right) 1.48 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Arm fat percentage (left) 1.80 2 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5
Handedness (chirality/laterality): Left-handed 1.52 1 0 0.0 0.00 1.0e+00 FES
Long-standing illness, disability or infirmity 2.46 1 0 0.0 0.00 1.0e+00 CDKN2B
Diabetes diagnosed by doctor 1.93 1 0 0.0 0.00 1.0e+00 SLC22A3
Medication for cholesterol 6.92 3 1 3.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Breast cancer (self-reported) 2.49 1 0 0.0 0.00 1.0e+00 CDKN2B
Asthma (self-reported) 1.46 1 0 0.0 0.00 1.0e+00 FES
Medication: Aspirin 17.52 7 5 15.2 0.99 5.0e-06 CDKN2B CDKN2B-AS1 FES PSRC1 RP11-288H12.3 RP11-731C17.2 SLC22A3
Illnesses of father: None of the above (group 1) 11.90 5 2 6.1 -0.99 6.3e-04 CDKN2B CDKN2B-AS1 FES RP11-731C17.2 SLC22A3
Whole body water mass 1.29 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Leg predicted mass (right) 1.49 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Arm fat mass (left) 1.79 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Number of self-reported non-cancer illnesses 3.06 1 0 0.0 0.00 1.0e+00 PSRC1
Average weekly champagne plus white wine intake 1.38 1 0 0.0 0.00 1.0e+00 RP11-288H12.3
Eye problems/disorders: Glaucoma 9.20 2 2 6.1 0.00 1.0e+00 CDKN2B CDKN2B-AS1
Medication: Blood pressure 6.20 2 1 3.0 0.00 1.0e+00 FES SLC22A3
Supplements: Fish oil (including cod liver oil) 2.70 1 0 0.0 0.00 1.0e+00 SLC22A3
High cholesterol (Self-reported) 28.66 6 3 9.1 0.81 5.2e-02 FES PSRC1 RP11-288H12.3 RP11-378J18.8 RP11-731C17.2 SLC22A3
Medication: Bendroflumethiazide 3.14 1 1 3.0 0.00 1.0e+00 FES
Medication: Paracetamol 2.42 2 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5
Medication: Lisinopril 2.22 1 0 0.0 0.00 1.0e+00 FES
Medication: Atorvastatin 19.10 5 2 6.1 0.99 1.4e-03 CDKN2B CDKN2B-AS1 PSRC1 RP11-288H12.3 SLC22A3
Illnesses of father: High blood pressure 5.14 1 1 3.0 0.00 1.0e+00 FES
Ever smoked 2.01 1 0 0.0 0.00 1.0e+00 FES
Basal metabolic rate 1.37 3 0 0.0 0.00 1.0e+00 FES PSRC1 SLC22A3
Leg fat percentage (left) 2.01 2 1 3.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5
Arm fat-free mass (left) 1.12 2 0 0.0 0.00 1.0e+00 PSRC1 SLC22A3
Risk taking 3.43 2 0 0.0 0.00 1.0e+00 FES RP11-731C17.2
Age started oral contraceptive pill 1.54 1 0 0.0 0.00 1.0e+00 FES
Diastolic blood pressure, automated reading 5.42 3 1 3.0 0.00 1.0e+00 CDKN2B CDKN2B-AS1 FES
Vascular/heart problems diagnosed by doctor 9.14 4 1 3.0 -0.96 4.1e-02 CDKN2B FES RP11-731C17.2 SLC22A3
Cholesterol lowering medication 15.71 5 2 6.1 0.95 1.3e-02 CDKN2B PSRC1 RP11-288H12.3 RP11-731C17.2 SLC22A3
Pain experienced in last month 1.86 1 0 0.0 0.00 1.0e+00 RP1-257A7.5
Basal cell carcinoma (self-reported) 3.08 1 0 0.0 0.00 1.0e+00 CDKN2B
Heart disease (siblings) 11.32 6 0 0.0 0.96 2.0e-03 CDKN2B CDKN2B-AS1 FES RP11-378J18.8 RP1-257A7.5 SLC22A3
Impedance of whole body 1.80 2 1 3.0 0.00 1.0e+00 PSRC1 RP11-731C17.2
Leg fat mass (left) 1.68 3 0 0.0 0.00 1.0e+00 RP11-731C17.2 RP1-257A7.5 SLC22A3
Arm predicted mass (left) 1.22 2 0 0.0 0.00 1.0e+00 PSRC1 SLC22A3

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 1 0.0286 1.34
GTEx Adipose Visceral Omentum 0 0.0000 1.30
GTEx Adrenal Gland 0 0.0000 1.34
GTEx Artery Aorta 3 0.1008 1.41
GTEx Artery Coronary 1 0.0845 1.39
GTEx Artery Tibial 4 0.1064 1.42
GTEx Brain Caudate basal ganglia 0 0.0000 1.29
GTEx Brain Cerebellar Hemisphere 3 0.2015 1.31
GTEx Brain Cerebellum 1 0.0505 1.38
GTEx Brain Cortex 0 0.0000 1.26
GTEx Brain Frontal Cortex BA9 0 0.0000 1.29
GTEx Brain Hippocampus 0 0.0000 1.14
GTEx Brain Hypothalamus 1 0.1695 1.35
GTEx Brain Nucleus accumbens basal ganglia 0 0.0000 1.22
GTEx Brain Putamen basal ganglia 0 0.0000 1.37
GTEx Breast Mammary Tissue 1 0.0507 1.31
GTEx Breast Mammary Tissue (Male) 0 0.0000 1.28
GTEx Breast Mammary Tissue (Female) 1 0.0608 1.25
GTEx Cells EBV-transformed lymphocytes 0 0.0000 1.25
GTEx Cells Transformed fibroblasts 3 0.0714 1.31
GTEx Colon Sigmoid 1 0.0684 1.31
GTEx Colon Transverse 0 0.0000 1.27
GTEx Esophagus Gastroesophageal Junction 1 0.0692 1.29
GTEx Esophagus Mucosa 1 0.0301 1.28
GTEx Esophagus Muscularis 2 0.0619 1.31
GTEx Heart Atrial Appendage 0 0.0000 1.34
GTEx Heart Left Ventricle 0 0.0000 1.28
GTEx Liver 1 0.1395 1.28
GTEx Lung 1 0.0348 1.36
GTEx Muscle Skeletal 1 0.0346 1.31
GTEx Nerve Tibial 2 0.0463 1.32
GTEx Ovary 1 0.1101 1.28
GTEx Pancreas 0 0.0000 1.29
GTEx Pituitary 0 0.0000 1.31
GTEx Prostate 1 0.1198 1.28
GTEx Skin Not Sun Exposed Suprapubic 0 0.0000 1.32
GTEx Skin Sun Exposed Lower leg 2 0.0549 1.34
GTEx Small Intestine Terminal Ileum 0 0.0000 1.25
GTEx Spleen 0 0.0000 1.40
GTEx Stomach 0 0.0000 1.36
GTEx Testis 0 0.0000 1.23
GTEx Thyroid 0 0.0000 1.34
GTEx Uterus 0 0.0000 1.29
GTEx Vagina 0 0.0000 1.37
GTEx Whole Blood 1 0.0502 1.28
METSIM Adipose 0 0.0000 1.28
NTR Blood 0 0.0000 1.30
ROSMAP Brain Pre-frontal Cortex 1 0.0228 1.29
YFS Blood 0 0.0000 1.21
CommonMind Brain Pre-frontal Cortex 4 0.0744 1.32
TCGA Breast Tumor 0 0.0000 1.18
TCGA Breast Normal 0 0.0000 1.19
TCGA Ovarian Tumor 1 0.0342 1.20
TCGA Prostate Tumor 0 0.0000 1.21